Dr. Chuang is an Assistant Professor for the Charles Bronfman Institute for Personalized Medicine and the Department of Genetics and Genomic Sciences. Dr. Chuang has more than seven years of experience conducting functional studies on genetic mutations underlying susceptibility to inflammatory bowel disease (IBD). He has a strong background in the fields of genetics, genomics, biochemistry, molecular, and developmental biology. In his 2021 publications in Gastroenterology, Dr. Chuang applied cutting-edge single-cell RNAseq technologies in humans, zebrafish IBD models, immune cells, and cell lines to identified potential therapeutics of IBD based on precision genetics. His 2019 publication in Disease Models and Mechanisms established a novel zebrafish intestinal injury models for IBD in vivo functional studies. With his current work, Dr. Chuang is utilizing zebrafish to model intestinal injury, bacterial exposures, and medications to define epithelial in vivo responses relevant to human IBD. His 2016 publication in Gastroenterology identified an Ashkenazi Jewish-predominant heterozygous frameshift mutation in CSF2RB, increasing the risk for Crohn’s disease attenuates GM-CSF signaling.
Multi-Disciplinary Training Area
Genetics and Genomic Sciences [GGS]Education
BA, National Taiwan University
MS, New York University
PhD, Rutgers University
-
2019
MSSM-GGS Pilot Project funding -
2019
Visiting IBD Research Fellowship (#620146) -
2018
ASHG Trainee Paper Spotlight -
2017
Winner of 8th Icahn School of Medicine at Mount Sinai (ISMMS) Postdoctoral Symposium DataBlitz -
First place award at MSSM IBD RETREAT 2017
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Chuang did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.